ZFZiling Fang

Ziling Fang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ziling Fang has a total of 103 co-authors. Here are the top co-authors by number of shared publications:

  • Xiaojun Xiang

    Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China

    14 shared publications
  • Ling Zhou

    Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, P.R. China

    13 shared publications
  • Min Zhong

    Department of Oncology the First Affiliated Hospital, Jiangxi Medical College, Nanchang University Nanchang Jiangxi P.R. China

    9 shared publications
  • Yi Le

    Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, P.R. China

    9 shared publications
  • Yan He

    Department of Oncology, the First Affiliated Hospital of Nanchang University, Nanchang, People’s Republic of China

    8 shared publications
  • Xianpin Wei

    Department of Oncology the First Affiliated Hospital, Jiangxi Medical College, Nanchang University Nanchang Jiangxi P.R. China

    6 shared publications

Latest Publications

  • Open Access

    Constitutional mismatch repair deficiency presenting with six primary malignancies over nearly 8 years: a case report

    by Mengxiang Xiao, Ling Zhou, Li Li, Jinbo Zhan, Weiqi Liu, Yi Le, Liping Liu, Junyao Cheng, Guangxiang Ding, Yexian Zeng, et al.

  • Open Access

    MicroRNA-targeted reprogramming of CD8+ T cells against cancer

    by Yuchen Mao, Yujin Liu, Kaiyan Jing, Yiqing Shao, Kangping Yang, Jiaqiang Wu, Xianhuan Zhou, Heng Wang, Ziling Fang

    This scoping review highlights the critical role of microRNAs (miRNAs) in mediating the bidirectional crosstalk between CD8+ T cells and tumor cells within the immunosuppressive tumor microenvironment (TME). Specific miRNAs (e.g., miR-155, miR-340-5p) orchestrate CD8+ T cell function by fine-tuning immune checkpoints (PD-1/PD-L1), metabolic reprogramming, and epigenetic states. Conversely, CD8+ T cells influence tumor behavior via exosomal miRNA transfer (e.g., miR-765). Our analysis reveals both pan-cancer mechanisms, such as PD-1/PD-L1 regulation, and tissue-specific miRNA functions (e.g., miR-143 in melanoma). To overcome translational challenges like off-target effects, innovative delivery strategies using lipid nanoparticles and engineered exosomes are being developed. This review provides a mechanistic framework for miRNA-mediated interactions, offers clinical insights for novel combination therapies, and assesses future directions, thereby advancing the development of precision immunotherapies.


  • Open Access

    Immune checkpoint inhibitor resistance in dMMR high-grade intraepithelial neoplasia with lynch syndrome-associated colon cancer: a case report

    by Liping Liu, Ling Zhou, Hongjiao Zhang, Yan He, Juanjuan Zhou, Yi Le, Weiqi Liu, Jinbo Zhan, Ziling Fang, Li Li, et al.

    Immune checkpoint inhibitors demonstrate high efficacy in MSI-H/dMMR colorectal cancer, yet a subset of patients develops resistance. This case reports in


  • Open Access

    UCHL3 depletion inhibits gastric cancer progression and enhances palbociclib sensitivity by regulating the AKT/CCND1 signaling axis via ENO1 ubiquitination

    by Weiqi Liu, Ling Zhou, Yi Le, Yan He, Juanjuan Zhou, Hongjiao Zhang, Jinbo Zhan, Tingting Hu, Jingru Wang, Yun Lin, et al.

    Ubiquitin carboxyl-terminal hydrolase L3 (UCHL3) is a deubiquitinating enzyme involved in various cancers, yet its role in gastric cancer (GC) requires further exploration. This study primarily investigates the expression, function, and mechanisms of UCHL3 in GC. Clinical samples and bioinformatics analysis indicated that UCHL3 is overexpressed in GC tissues compared to adjacent normal tissues, with higher expression levels correlating with worse prognosis. Functional assays demonstrated that UCHL3 promotes GC cell proliferation, invasion, and migration, accelerates cell cycle progression, and induces epithelial–mesenchymal transition (EMT). In vivo studies using a cell line-derived xenograft (CDX) model confirmed that UCHL3 enhances GC proliferation, and its therapeutic potential was validated in patient-derived xenografts (PDX). Mechanistically, transcriptomic analysis and validation experiments identified the AKT/CCND1 signaling pathway as a key mediator of UCHL3-driven GC progression. Co-immunoprecipitation (Co-IP) and liquid chromatography-mass spectrometry identified potential UCHL3-binding proteins, notably the AKT activator ENO1. Molecular docking simulations, Co-IP, and GST-pull down assays further confirmed the interaction, mapping the binding regions between UCHL3 (AA 179-230) and ENO1 (AA 140-434). Cycloheximide (CHX) and in vivo ubiquitination assays demonstrated that UCHL3 deubiquitinates and stabilizes ENO1, thus extending its half-life, while UCHL3 inhibition produced the opposite effect. A C95A point mutation significantly impaired UCHL3’s deubiquitination function on ENO1. Further studies revealed UCHL3 removes K48-linked polyubiquitin chains from ENO1 at lysine 92, activating the AKT/CCND1 signaling pathway. In addition, the small-molecule inhibitor TCID, specific for UCHL3, inhibited this deubiquitination, counteracting pro-tumorigenic effects. In vitro and in vivo experiments demonstrated that TCID increased the sensitivity of GC cells to CDK4/6 inhibitors palbociclib. These findings suggest that UCHL3 contributes to GC progression and represents a promising therapeutic target for GC treatment.


  • Open Access

    Therapeutic potential of TRIM family proteins in gastric cancer: from signaling pathway regulation to precision targeting strategies

    by Caiqing Zhao, Jialing Qi, Zhenze Zhang, Qi Feng, Ziling Fang, Nian Fang

    Gastric cancer (GC) is a globally prevalent malignant tumor, causing approximately 770,000 deaths in 2020, ranking fourth among all cancers. The tripartite motif (TRIM) protein family is involved in various cellular regulations and has become a key player in the pathogenesis of gastric cancer. This review explores the therapeutic potential of TRIM proteins in gastric cancer, from signaling pathway regulation to precision targeting strategies. Structurally, there are differences in the C-terminal domain of TRIM proteins, which determine their subgroup classification and substrate recognition. Functionally, they regulate multiple signaling pathways that are crucial for the development of gastric cancer. Clinically, many TRIM proteins serve as promising diagnostic and prognostic biomarkers. In terms of therapy, targeting TRIM proteins holds great potential. Strategies include developing small molecule inhibitors targeting specific TRIM domains, such as inhibitors targeting the bromodomain of TRIM24, and exploring PROTAC technology to degrade oncogenic TRIM proteins. Combination immunotherapy targeting TRIM-related pathways may also provide new therapeutic options. However, challenges persist, Including limited understanding of heterotypic polyubiquitination targets/functions of TRIM proteins, insufficient mechanistic/epidemiological insights into their immunomodulatory roles in the tumor microenvironment, underdeveloped TRIM inhibitors for gastric cancer, unevaluated pharmacokinetics/toxicity of inhibitors in preclinical models, and the need to construct complete TRIM biological systems. In summary, TRIM proteins are deeply involved in the biological processes of gastric cancer, and understanding their functions and regulation could lead to the development of more effective precision targeting strategies for gastric cancer treatment.

  • Open Access

    TRIM47 Facilitates Osteosarcoma Progression via Destabilising FBP1 and Thus Activation of Wnt/β‐Catenin Pathway

    by Heng Wang, Xiao Chen, Fengting Nie, Min Zhong, Zhi Fang, Zezhi Qiu, Ling Zhou, Yi Le, Xianpin Wei, Yanyu Liao, et al.

    Osteosarcoma is a malignant bone tumour with a high rate of disability and mortality in adolescents. Tripartite motif containing 47 (TRIM47) upregulation contributed greatly to carcinogenesis and progression in several tumours, while its role in osteosarcoma (OS) is still unclear and needs further investigation. In this study, we first evidenced that TRIM47 was frequently upregulated in osteosarcoma tissues and cell lines, and the higher TRIM47 expression predicted poor outcomes for osteosarcoma patients. Moreover, TRIM47 depletion impeded cell proliferation, migration, and invasion of osteosarcoma cells, while TRIM47 overexpression elicited opposite effects. Mechanistically, TRIM47 interacted with and accelerated the degradation of fructose 1, 6‐bisphosphatase 1 (FBP1) by inducing its ubiquitination, subsequently activating the Wnt/β‐catenin signalling pathway. Furthermore, knockdown of FBP1 reversed the functions of TRIM47 depletion in OS cells. More notably, our in vivo assays showed that loss of TRIM47 slowed the growth rate of osteosarcoma xenograft tumours. Overall, our data indicated that TRIM47 facilitates OS progression by promoting proteasomal degradation of FBP1, thereby activating the Wnt/β‐catenin pathway, which clarified that targeting the TRIM47‐FBP1‐β‐catenin axis could be a promising approach for treating OS.


  • Open Access

    Random forest-driven mortality prediction in critical IBD care: a dual-database model integrating comorbidity patterns and real-time physiometrics

    by Zhenze Zhang, Caiqing Zhao, Yijun Zhou, Ling Yao, Peng Liu, Ziling Fang, Nian Fang

    Background: Inflammatory bowel disease (IBD) poses significant mortality risks for critically ill patients requiring intensive care unit (ICU) admission, driven by complications such as malnutrition, thromboembolism, and multi-organ dysfunction. Current prognostic tools for mortality prediction in this population remain limited. Machine learning (ML) offers advantages in handling complex clinical data but has not been systematically applied to this high-risk cohort. This multicenter study aimed to develop and validate ML-based models for mortality risk stratification in critically ill IBD patients using large-scale ICU databases.Methods: Data from 551 IBD patients in the MIMIC-IV database (2008–2019) were analyzed, with external validation using the eICU dataset. Nine ML algorithms (XGBoost, logistic regression, LightGBM, random forest, decision tree, elastic net, MLP, KNN, RSVM) were trained to predict 1-year mortality. Predictors included demographics, comorbidities, laboratory parameters, vital signs, and disease severity scores. Missing data ( 0.8). Nine predictors were identified: malignancy history, Charlson Comorbidity Index (CCI), Red Cell Distribution Width (Rdw), Glasgow Coma Scale (GCS), Sequential Organ Failure Assessment (Sofa), age, heart rate, weight and gender. The nomogram demonstrated robust external validation performance in the eICU cohort (AUC > 0.8).Conclusion: We developed and validated a machine learning-based nomogram to predict mortality in critically ill IBD patients, integrating interpretable predictors from multicenter ICU data.


  • Open Access

    Pan-cancer analysis of oncogenic role of MAGOH and experiment validation in hepatocellular carcinoma

    by Zezhi Qiu, Yi Le, Yanyu Liao, Xiao Chen, Xing Xin, Fengting Nie, Xianpin Wei, Heng Wang, Ziling Fang

    Several studies have highlighted that Mago-nashi homolog (MAGOH) contributed greatly to cell development, growth, and malignant progression in multiple cancer types. Nevertheless, the role of MAGOH in pan-cancer datasets, particularly in hepatocellular carcinoma (HCC), remains uninvestigated. In this study, we first utilized diverse databases to systematically analyze the expression and significance of MAGOH across pan-cancer. Besides, we validated the clinical significance and biological functions of MAGOH in HCC via clinical specimens and in vitro experiments. Bioinformatic analysis has demonstrated that MAGOH was frequently overexpressed in multiple tumors compared to adjacent non-cancerous tissues. Moreover, high expression of MAGOH was related to poorer overall survival (OS), disease-specific survival (DSS), disease-free interval (DFI), and progression-free interval (PFI) in certain malignancies, notably an independent prognostic predictor for liver hepatocellular carcinoma (LIHC). Furthermore, MAGOH was closely correlated with immune cell infiltration, immune checkpoint expression, tumor mutational burden (TMB), microsatellite instability (MSI), and mismatch repair (MMR) status. Subsequently, we found that the expression of MAGOH was largely increased in clinical HCC tissues (34/60, 56.7%) compared to non-cancerous tissues. Additionally, MAGOH was positively correlated with advanced TNM staging and vascular invasion. More convincingly, MAGOH upregulation facilitated cell proliferation, migration, and invasion of HCC cells, while MAGOH depletion elicited opposite effects. Collectively, our study conducted a comprehensive analysis of the hitherto undescribed role of MAGOH in pan-cancer by analyzing multi-omics data. More significantly, we recognized MAGOH as a crucial promoter in the malignant progression of hepatocellular carcinoma, providing potential therapeutic targets for HCC patients.


  • Open Access

    Multiple mechanisms and applications of tertiary lymphoid structures and immune checkpoint blockade

    by Zelin Li, Shuhan Liu, Deyu Liu, Kangping Yang, Jing Xiong, Ziling Fang

    Background: Immune checkpoint blockade (ICB) inhibits tumor immune escape and has significantly advanced tumor therapy. However, ICB benefits only a minority of patients treated and may lead to many immune-related adverse events. Therefore, identifying factors that can predict treatment outcomes, enhance synergy with ICB, and mitigate immune-related adverse events is urgently needed. Main text: Tertiary lymphoid structures (TLS) are ectopic lymphoid tissues that arise from the tumor periphery. They have been found to be associated with better prognosis and improved clinical outcomes after ICB therapy. TLS may help address the problems associated with ICB. The multiple mechanisms of action between TLS and ICB remain unknown. This paper described potential mechanisms of interaction between the two and explored their potential applications.


  • SNX5 facilitates the progression of gastric cancer by increasing the membrane localization of LRP5

    by Yi Le, Ling Zhou, Yan He, Juanjuan Zhou, Jinbo Zhan, Hongjiao Zhang, Xiao Chen, Jianping Xiong, Ziling Fang, Xiaojun Xiang

    Endocytosis is essential for cancer cell motility, which is predominantly mediated by the sorting nexin (SNX) family. Previous studies have demonstrated that SNX5 is elevated in several tumors, while its clinical significance and underlying mechanism in gastric cancer (GC) remain uninvestigated. In this study, we reported that SNX5 is highly expressed in GC and promotes the malignant biological behavior of GC cells. Its upregulation is closely related to poor prognosis in GC patients. Mechanistically, we observed an interaction between SNX5 and low-density lipoprotein receptor-related protein5 (LRP5) in GC cells. SNX5 inhibits LRP5 internalization and promotes its recycling to the cell membrane, which prevents LRP5 from being degraded in the lysosome. The increased membrane localization of LRP5 facilitates β-catenin stabilization, thus activating the Wnt signaling pathway, leading to tumorigenesis and progression.